Home Enzyme Replacement Therapy in Gaucher Disease: A Review

被引:0
|
作者
Kiec-Wilk, Beata [1 ,2 ]
Guijt, Paul [3 ]
Dan, Michaela [4 ]
Abdelwahab, Magy [5 ]
Revel-Vilk, Shoshana [6 ,7 ]
Serratrice, Christine [8 ,9 ]
机构
[1] Jagiellonian Univ, Med Coll, Dept Pathophysiol, Unit Rare Metab Dis, PL-31121 Krakow, Poland
[2] St John Paul II Specialist Hosp, Metab Dis Clin, PL-31202 Krakow, Poland
[3] Int Gaucher Alliance, London EC2A 4NE, England
[4] Romanian Gaucher Assoc, Cluj Napoca 400540, Romania
[5] Cairo Univ, Kasr ELainy Hosp, Pediat Hematol & BMT Dept & Gaucher Dis Clin, Pediat Hosp, Cairo 11562, Egypt
[6] Shaare Zedek Med Ctr, Gaucher Unit, Eisenberg R&D Author, IL-9103102 Jerusalem, Israel
[7] Hebrew Univ Jerusalem, Fac Med, IL-9103102 Jerusalem, Israel
[8] Univ Hosp Geneva, Div Internal Med Aged, CH-1256 Geneva, Switzerland
[9] Univ Geneva, Sch Med, CH-1206 Geneva, Switzerland
关键词
Gaucher disease; home therapy; enzyme replacement therapy; safety; compliance; MUCOPOLYSACCHARIDOSIS TYPE-I; LYSOSOMAL STORAGE DISORDERS; VELAGLUCERASE ALPHA; ADULT PATIENTS; FABRY-DISEASE; TYPE-1; SAFETY; INFUSION; IMIGLUCERASE; IMPACT;
D O I
10.3390/jcm14030842
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since the early 1990s, Gaucher Disease has been a pioneering condition for home-based enzyme replacement therapy (ERT), marking a significant shift in patient care. Since then, many countries have adopted this approach. However, home ERT is not possible in all countries. Objectives: The aim of this article is to explore the implementation of home ERT for Gaucher disease, focusing on patient expectations, safety, compliance, economic benefits, and practical considerations. Methods: The PRISMA reporting protocol was followed, focusing on articles about home ERT for Gaucher Disease. Results: Twenty articles were analyzed in the review, revealing promising outcomes. Home ERT has consistently been shown to be safe, to improve patients' quality of life, to reduce the utilization of hospital resources, and to pose no compliance issues. Conclusions: We believe it is essential to expand the availability of home ERT for Gaucher Disease to all countries where ERT is accessible. Based on the literature review, we present the conditions that must be met before starting home ERT programs.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Enzyme replacement therapy improves erythropoiesis and iron dysregulation in Gaucher disease
    Motta, Irene
    Delbini, Paola
    Scaramellini, Natalia
    Ghiandai, Viola
    Duca, Lorena
    Nava, Isabella
    Nascimbeni, Fabio
    Lugari, Simonetta
    Consonni, Dario
    Trombetta, Elena
    Di Stefano, Valeria
    De Amicis, Margherita Migone
    Cassinerio, Elena
    Carubbi, Francesca
    Cappellini, Maria Domenica
    ANNALS OF HEMATOLOGY, 2024, 103 (12) : 5113 - 5121
  • [22] Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India
    A. Nagral
    P. Mewawalla
    S. Jagadeesh
    M. Kabra
    S. R. Phadke
    I. C. Verma
    R. D. Puri
    N. Gupta
    P. S. Kishnani
    P. K. Mistry
    Indian Pediatrics, 2011, 48 : 779 - 784
  • [23] Recombinant Macrophage Targeted Enzyme Replacement Therapy for Gaucher Disease in India
    Nagral, A.
    Mewawalla, P.
    Jagadeesh, S.
    Kabra, M.
    Phadke, S. R.
    Verma, I. C.
    Puri, R. D.
    Gupta, N.
    Kishnani, P. S.
    Mistry, P. K.
    INDIAN PEDIATRICS, 2011, 48 (10) : 779 - 784
  • [24] Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
    Istaiti, Majdolen
    Becker-Cohen, Michal
    Dinur, Tama
    Revel-Vilk, Shoshana
    Zimran, Ari
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (21)
  • [25] Enzyme replacement therapy in adult patients with type I Gaucher disease
    Ponomarev, R., V
    Lukina, E. A.
    TERAPEVTICHESKII ARKHIV, 2019, 91 (07) : 127 - 131
  • [26] Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy
    Weinreb, Neal J.
    Barbouth, Deborah S.
    Lee, Robert E.
    BLOOD CELLS MOLECULES AND DISEASES, 2018, 68 : 211 - 217
  • [27] Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy
    Wine, Eytan
    Yaniv, Isaac
    Cohen, Ian J.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2007, 29 (07) : 451 - 457
  • [28] Clinical efficacy of enzyme replacement therapy in Fabry disease. A critical review
    Lidove, O.
    Papo, T.
    REVUE DE MEDECINE INTERNE, 2009, 30 (10): : 920 - 929
  • [29] Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy
    Kuter, David J.
    Wajnrajch, Michael
    Hernandez, Betina
    Wang, Rong
    Chertkoff, Raul
    Zimran, Ari
    BLOOD CELLS MOLECULES AND DISEASES, 2020, 82
  • [30] Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease
    Laura van Dussen
    Marieke Biegstraaten
    Carla EM Hollak
    Marcel GW Dijkgraaf
    Orphanet Journal of Rare Diseases, 9